VOR Stock Price, Vor Biopharma Inc. Quote, Chart

Market Summary

USD1.81+0.01

Market Closed

0.56%

VOR Stock Price

View Fullscreen

VOR RSI Chart

VOR Valuation

Market Cap

123.5M

Price/Earnings (Trailing)

-1.03

Price/Free Cashflow

-1.15

VOR Price/Earnings (Trailing)

VOR Profitability

Return on Equity

-97.72%

Return on Assets

-71.98%

Free Cashflow Yield

-87.07%

VOR Fundamentals

VOR Earnings

Earnings (TTM)

-120.2M

Earnings Growth (Yr)

-8.34%

Earnings Growth (Qtr)

-17.3%

Breaking Down VOR Revenue

Last 7 days

5.9%

Last 30 days

4.6%

Last 90 days

-12.1%

Trailing 12 Months

-58.4%

How does VOR drawdown profile look like?

VOR Financial Health

Current Ratio

8.46

VOR Investor Care

Shares Dilution (1Y)

1.95%

Diluted EPS (TTM)

-1.77

Tracking the Latest Insider Buys and Sells of Vor Biopharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	chakraborty tirtha	sold (taxes)	-1,531	1.75	-875	chief scientific officer
May 06, 2024	ang robert	sold (taxes)	-4,131	1.75	-2,361	president and ceo
May 06, 2024	attar eyal c.	sold (taxes)	-1,748	1.75	-999	chief medical officer
May 06, 2024	jorgensen nathan d.	sold (taxes)	-1,459	1.75	-834	chief financial officer
May 01, 2024	ang robert	sold (taxes)	-4,869	1.77	-2,751	president and ceo
May 01, 2024	jorgensen nathan d.	sold (taxes)	-1,623	1.77	-917	chief financial officer
May 01, 2024	chakraborty tirtha	sold (taxes)	-1,743	1.77	-985	chief scientific officer
May 01, 2024	attar eyal c.	sold (taxes)	-2,028	1.77	-1,146	chief medical officer
Mar 01, 2024	jorgensen nathan d.	sold (taxes)	-14,323	2.27	-6,310	chief financial officer
Mar 01, 2024	chakraborty tirtha	sold (taxes)	-12,657	2.27	-5,576	chief scientific officer

Which funds bought or sold VOR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	reduced	-57.4	-2,912,000	2,370,000	0.06%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.12	-4,858	9,094	-%
May 16, 2024	JANE STREET GROUP, LLC	added	15.03	8,070	46,196	-%
May 16, 2024	COMERICA BANK	new	-	6,307	6,307	-%
May 15, 2024	LMR Partners LLP	reduced	-19.98	-18,074	96,926	-%
May 15, 2024	STATE STREET CORP	added	8.17	190,750	1,558,770	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	unchanged	-	2,729,870	53,914,800	0.69%
May 15, 2024	DEUTSCHE BANK AG\	unchanged	-	3,820	75,449	-%
May 15, 2024	MORGAN STANLEY	reduced	-26.37	-86,876	300,261	-%
May 15, 2024	HSBC HOLDINGS PLC	new	-	41,961	41,961	-%

Are Funds Buying or Selling VOR?

Are funds buying VOR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VOR

No. of Funds

Unveiling Vor Biopharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	5am ventures vi, l.p.	6.8%	4,595,089	SC 13D/A
Feb 14, 2024	paradigm biocapital advisors lp	9.5%	6,457,293	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Aug 11, 2023	ra capital management, l.p.	33.7%	22,780,343	SC 13D/A
Feb 14, 2023	paradigm biocapital advisors lp	9.9%	6,477,999	SC 13G/A
Jan 10, 2023	fmr llc	-	0	SC 13G/A
Dec 09, 2022	ra capital management, l.p.	34.8%	22,760,145	SC 13D/A
Nov 14, 2022	ra capital management, l.p.	28.78%	11,131,300	SC 13D/A
Oct 27, 2022	paradigm biocapital advisors lp	6.1%	2,328,494	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G/A

Recent SEC filings of Vor Biopharma Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 02, 2024	8-K	Current Report

Peers (Alternatives to Vor Biopharma Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vor Biopharma Inc. News

Latest updates

Vor Biopharma Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-15.7%	167	198	223	251	278	299	206	225	234	243	259	275	293	76.00
Current Assets	-20.6%	112	141	164	191	217	237	143	159	190	214	232	249	266	49.00
Cash Equivalents	43.4%	45.00	31.00	45.00	32.00	42.00	58.00	61.00	63.00	90.00	120	143	170	263	49.00
Net PPE	-8.8%	9.00	10.00	11.00	11.00	12.00	13.00	13.00	15.00	12.00	7.00	6.00	6.00	6.00	5.00
Liabilities	-7.2%	44.00	47.00	48.00	47.00	47.00	49.00	48.00	50.00	40.00	26.00	26.00	25.00	26.00	28.00
Current Liabilities	-15.1%	13.00	16.00	15.00	13.00	13.00	13.00	11.00	12.00	18.00	10.00	9.00	8.00	9.00	10.00
Shareholder's Equity	-18.4%	123	151	175	204	230	251	159	175	194	216	233	250	267	-
Retained Earnings	-9.1%	-370	-340	-313	-280	-250	-222	-198	-174	-152	-130	-111	-93.32	-74.95	-61.22
Additional Paid-In Capital	0.6%	494	491	489	486	481	474	358	351	348	346	345	343	342	2.00
Shares Outstanding	0.5%	68.00	68.00	68.00	67.00	67.00	66.00	38.00	37.00	37.00	37.00	32.00	37.00	-	-
Float	-	-	-	-	136	-	-	-	116	-	-	-	352	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-26.8%	-30,465	-24,026	-27,898	-24,100	-24,268	-18,346	-18,902	-24,992	-22,904	-17,587	-17,343	-16,565	-17,649	-13,634	-8,245	-8,328	-6,085
Share Based Compensation	62.7%	3,081	1,894	3,162	4,238	4,068	3,879	3,329	1,741	1,746	1,203	1,154	1,067	891	594	483	153	112
Cashflow From Investing	325.5%	43,973	10,335	40,536	13,639	6,498	-97,036	12,702	-2,702	-7,055	-5,953	-8,486	-76,041	-1,171	-1,477	-1,587	-552	-545
Cashflow From Financing	284.0%	96.00	25.00	176	218	2,519	112,261	4,075	604	200	307	201	-445	232,848	46.00	526	64,192	17,762

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VOR Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 24,322	$ 21,915
General and administrative	8,004	8,507
Total operating expenses	32,326	30,422
Loss from operations	(32,326)	(30,422)
Other income:
Interest income	1,522	1,989
Total other income	1,522	1,989
Net loss	$ (30,804)	$ (28,433)
Net loss per share attributable to common stockholders, basic	$ (0.45)	$ (0.43)
Net loss per share attributable to common stockholders, diluted	$ (0.45)	$ (0.43)
Weighted-average common shares outstanding, basic	68,030,966	66,265,703
Weighted-average common shares outstanding, diluted	68,030,966	66,265,703
Other comprehensive income (loss):
Unrealized (loss) gain on available for sale marketable securities	$ (10)	$ 596
Total other comprehensive (loss) income	(10)	596
Comprehensive loss	$ (30,814)	$ (27,837)

VOR Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 44,964	$ 31,360
Marketable securities	62,515	105,815
Prepaid expenses	3,831	3,153
Other current assets	507	475
Total current assets	111,817	140,803
Restricted cash equivalents	2,413	2,413
Property and equipment, net	9,165	10,050
Operating lease right-of-use assets	38,816	40,048
Other assets	4,819	4,812
Total assets	167,030	198,126
Current liabilities:
Accounts payable	2,325	815
Accrued liabilities	6,797	10,877
Operating lease liabilities	3,957	3,830
Other current liabilities	134	50
Total current liabilities	13,213	15,572
Long-term liabilities:
Operating lease liabilities—non-current	30,782	31,830
Total liabilities	43,995	47,402
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 68,223,496 and 67,901,610 shares issued and 68,215,771 and 67,891,311 outstanding as of March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	493,999	490,874
Accumulated other comprehensive loss	(87)	(77)
Accumulated deficit	(370,884)	(340,080)
Total stockholders' equity	123,035	150,724
Total liabilities and stockholders' equity	$ 167,030	$ 198,126

About Vor Biopharma Inc.

Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
WEBSITE	vorbio.com
INDUSTRY	Biotechnology
EMPLOYEES	133

Vor Biopharma Inc. Frequently Asked Questions

What is the ticker symbol for Vor Biopharma Inc.? What does VOR stand for in stocks?

VOR is the stock ticker symbol of Vor Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vor Biopharma Inc. (VOR)?

As of Fri May 17 2024, market cap of Vor Biopharma Inc. is 123.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VOR stock?

You can check VOR's fair value in chart for subscribers.

What is the fair value of VOR stock?

You can check VOR's fair value in chart for subscribers. The fair value of Vor Biopharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vor Biopharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VOR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vor Biopharma Inc. a good stock to buy?

The fair value guage provides a quick view whether VOR is over valued or under valued. Whether Vor Biopharma Inc. is cheap or expensive depends on the assumptions which impact Vor Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VOR.